IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07), Zacks reports. During the same quarter in the previous year, the business earned ($0.53) earnings per share.
IDEAYA Biosciences Stock Performance
Shares of NASDAQ IDYA traded down $1.53 during trading on Tuesday, hitting $18.94. 346,943 shares of the company traded hands, compared to its average volume of 969,645. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -5.80 and a beta of 0.26. The business's fifty day moving average is $17.89 and its 200 day moving average is $22.93. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $44.42.
Analyst Ratings Changes
Several equities analysts have issued reports on IDYA shares. Stephens restated an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $53.58.
View Our Latest Analysis on IDEAYA Biosciences
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
